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THE ROLE OF CERULOPLASMIN IN COLITIS

BAKYTZHAN BAKHAUTDIN

ABSTRACT
Ceruloplasmin (Cp) is an acute phase, plasma protein with multiple enzymatic activities
consistent with both pro- and anti-inflammatory functions. Our laboratory has recently
reported the presence of Cp in intestinal epithelial cells. To determine the potential role
of Cp in intestinal inflammation, we induced colitis in Cp-deficient mice by continuous
administration of dextran sodium sulfate (DSS) ad libitum in the drinking water. The Cpnull mice rapidly lost weight and all were moribund by day 14, while about 90% of the
wild-type (WT) mice survived at least 20 days. Higher amounts of TNF-, and neutrophil
(KC) and macrophage (MCP-1) chemokines, were detected in colon culture supernatants
in Cp-null mice compared to WT controls. Cp-null mice also exhibited excessive colonic
bleeding after 5 days, which correlated with elevated white blood cells, neutrophils, and
lymphocytes in the blood, and higher histopathology. Depletion of commensal microflora
by antibiotic treatment demonstrated that excessive inflammation in Cp-null animals is
microbiota-independent. Interestingly, microbiota-depleted Cp-null animals appear to
have higher epithelial damage caused by DSS since they become moribund about 10 days
earlier than WT controls. We have investigated the protective mechanism of Cp by
injection of Cp into knockout mice. Unexpectedly, mimicking Cp secretion by liver and
restoring blood Cp did not lessen the severity of inflammation. This finding was
supported by the transplantation of Cp-null bone marrow (BM) into WT controls and vice
versa; 90% of WT animals with Cp-null BM became moribund by day 14, whereas most
of the KO mice with WT BM survived until day 20 of DSS administration. Since
macrophages are the only source known to express Cp, we transferred WT macrophages
to Cp-null animals all of which survived continuous DSS challenge. Our results
demonstrate that Cp derived from macrophages contributes to the protection against
DSS-induced damage and colonic inflammation.
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CHAPTER I
INTRODUCTION

PART A. CERULOPLASMIN

Ceruloplasmin (Cp) was first characterized by Holmberg and Laurell in 1947 as a
copper-containing protein of the human plasma 1. Five years later Scheinberg & Gitlin
discovered that Wilson's disease patients have low levels of plasma Cp and designed a
biochemical test that is still in clinical use for this disease 2,3. The ferroxidase activity of
Cp, implied to play an important role of iron homeostasis, was demonstrated in 1966 4 by
a group led by Frieden 5. Since the determination of complete amino acid sequence and
the single-chain nature of human Cp published by Takahashi et al. in 1984 6, the
discoveries of its structure and function accelerated, and today we have the crystal
structure and know that it is expressed by several tissues but mainly by the liver, that its
ferroxidase activity makes it a potent antioxidant, and that it plays an important role in
iron metabolism and erythropoiesis 7, and the genetic disorders associated with it 8.

1

Expression of Ceruloplasmin
With total length of about 65 kb, the human Cp gene has been mapped on
chromosome 3q23-q24

9,10

. It is composed of 20 exons that eventually yield a single

polypeptide of 1046 amino acids

11

. The expression of Cp is induced by inflammatory

cytokines in response to inflammation, trauma, or infection 12. The main source of Cp is
liver where hepatocytes synthesize Cp and subsequently secrete it into the circulation 8.
Other sources of Cp include brain, lung, spleen, and testis
expressed by macrophage and brain astrocytes

13-15

. Interestingly, Cp is also

16,17

. There are two known alternatively

spliced forms of Cp, secreted and membrane-anchored. The membrane-anchored,
glycosylphosphatidylinositol (GPI)-linked version is formed by alternative splicing of
exons 19 and 20 in Cp gene and is found mainly in astrocytes, leptomeningeal
(membrane surrounding the brain) cells and Sertoli cells (testicular cells that provide
structural support) 18-21. The GPI-linked Cp is believed to have the same functions as does
the secreted form since only the last 5 amino acids of secreted Cp are replaced by 30
residues (which form the trans-membrane anchor) in membrane-bound form while the
rest of the protein remains the same 8.

2

Structure of Ceruloplasmin
Cp is a 132 KDa single chain polypeptide that folds into six structural domains
where each pair forms a larger domain of about 340 residues. These three larger domains
are structurally homologous to each other. Cp owes its name, light blue color, and
oxidase activity to the presence of copper atoms in its structure 8. Thus Cp is a member of
a multi-copper oxidase family including plant ascorbate oxidase. The multi-copper
oxidases contain three types of copper sites classified into type I, II, and III, depending on
their spectroscopic properties 22. There are three type I coppers present in the structure of
Cp responsible for the strong absorption at 600 nm, resulting in blue color. Four
imidazole nitrogens coordinate a single type II copper located close to two
antiferromagnetically coupled type III coppers. The type II and type III coppers
collectively are organized into a trinuclear copper cluster that serves as a site of oxygen
binding necessary for catalytic activity of the protein

23

. It has been suggested that the

loosely bound copper, termed seventh copper, of human ceruloplasmin is essential for the
expression of ceruloplasmin pro-oxidant activity in vitro, which opposes the previous
reports of antioxidant activity24.

Since Cp binds about 95% of plasma copper

25

, Cp was thought to be a copper

carrier that delivers the metal from the liver to various tissues 26,27 until discovery of other
copper carriers that share such function with Cp

28

. However, the focus of Cp-based

research shifted from copper to iron upon discovery of its ability to oxidize Fe2+ to Fe3+ 4.
Decreased ferroxidase activity in people with Cp deficiency is believed to affect the

3

development of several of neurodegenerative disorders such Alzheimer's and Parkinson's
diseases 17,29,30.

Figure 1.1. The crystal structure of human ceruloplasmin viewed by Swiss PDB Viewer.

4

The role of ceruloplasmin in iron metabolism
Dietary iron is absorbed by the epithelial cells of the small intestine (duodenum) 31
and then released into blood circulation. Cp facilitates basolateral iron transport by
oxidizing Fe2+ to Fe3+ to promotes incorporation of the latter into apo-transferrin

32

.

Evidence suggests that Cp also sustains iron uptake from blood circulation by cells of
various organs 33,34 and its GPI-anchored isoform, found in brain astrocytes 20, loads apotransferrin with ferric iron in a process preceded by oxidation of highly toxic form of iron
bringing the toxic Fe2+ in the cell to a minimum

18

. The process briefly outlined above

indicates the importance of Cp in iron metabolism and this concept has been strengthened
by findings in patients with a genetic Cp deficiency termed aceruloplasminemia. In this
rare genetic disorder the defect is caused by a mutation entailing premature termination
of Cp-mRNA translation which ultimately leads to pathologic iron accumulation in brain
and liver due to the role of Cp in iron transport 34-37.

The role of Cp is implicated in an effective control of the level of ferrous iron
oxidation since the advantage of the Cp-catalyzed iron oxidation is the absence of
hydrogen peroxide as an end product. Oxidation of Fe2+ by Cp with production of water
prevents accumulation of reactive oxygen species and further cytotoxicity 8. In other
words, Cp catalyzes the oxidation of ferrous iron to ferric in a reaction (shown below)
that does not yield radicals.
4 Fe2+ + O 2 + 4 H+ → 4 Fe3+ +2 H 2 O

5

The importance of membrane-anchored GPI-linked Cp expressed by astrocytes has
also been shown in iron metabolism

38

, where it regulates cellular iron efflux and

prevents its pathologic overload and toxicity. It is believed that membrane-anchored Cp
is involved in catecholamine oxidation, the disruption of which may result in
accumulation of reactive oxygen species and free radical-mediated reactions, contributing
to neurodegenerative disorders 8.

Although iron is an essential cofactor of multiple proteins and enzymes, its excess
is highly toxic. The iron levels in plasma is regulated by intestinal iron absorption via the
duodenal enterocyte and by release from spleen and liver

39

. It is thought that

ferrireductases at the apical surface of the epithelial cell reduces dietary ferric ion to
ferrous

40,41

, which is further transported across the gut epithelium by divalent metal

transporter-1

42

. A ferrous ion transporter called ferroportin, facilitates the basolateral

release of epithelial iron

43-45

with the aid of another enzyme called hephaestin, a

membrane-bound, Cp paralog with ferroxidase activity 46. On the other hand, plasma Cp
ferroxidase activity was thought to mobilize iron primarily from tissue stores

47

. The

important role of Cp in iron metabolism is most convincingly shown by iron
accumulation in liver, brain, and other tissues in patients with aceruloplasminemia 48.

Because since its transcript is not detected in the gastrointestinal tract 13-15 and iron
absorption is undiminished in Cp−/− mice 37,49, the role of in iron absorption was omitted.
Our laboratory have previously reported that the primary function of Cp under iron stress
(deficiency) is to increase iron absorption from the small intestines and not to release iron

6

from stores. Interestingly, the mechanism of stress-mediated iron absorption is
accompanied by a remarkable relocation of Cp to the duodenal lamina propria, where Cp
is thought to facilitate iron loading from ferroportin in the enterocyte basolateral
membrane to transferrin for subsequent transport by blood 32.

Aceruloplasminemia
Aceruloplasminemia is a rare hereditary disease identified by Miyajima et al in
1987 50. This autosomal recessive disease is caused by the complete systemic absence of
ceruloplasmin (Cp). Due to the role of Cp in iron homeostasis described earlier, its
deficiency results in iron deposition in the liver, pancreas, basal ganglia, and brain
Hellman and Gitlin

3

13

.

summarize the well-studied cases of aceruloplasminemia into at

least six missense mutations in Cp gene, six frame-shifts, three splice site and two
nonsense mutations as causes of Cp deletion on protein level.
As has been mentioned earlier, aceruloplasminemic patients do not develop serious
disorders of copper metabolism. However, many of them are diagnosed with marked
hemosiderosis (an iron overload disorder), mostly low levels of serum iron, and mild
anemia 51-54.

Neurological symptoms are usually detected in patients younger than the age of 40,
which is a result of extensive iron accumulation in the basal ganglia and retina. Ferrous
form of the iron is likely to contribute to the damaging effect of iron overload in tissues 8.
Because astrocytes express Cp and are believed to regulate tissue iron levels, iron
deposition within the nervous system is higher in astrocytes than in neurons which leads

7

to neurodegenerative symptoms including retinal degeneration. It is believed that freeradical stress is the cause of neuronal cell death observed in aceruloplasminemia. Due to
the evidence that shows high levels of lipid peroxidation in the brain of these patients, it
is likely ferrous iron contribute the increased cell death via a mechanism involving lipid
peroxidation provoked

52

. Interestingly, due to iron accumulation in the -cells of the

Langerhans islets, the disease is usually manifested by insulin-dependent diabetes
mellitus 55.

Cp-null mice
Harris et al, created an animal model of aceruloplasminemia by disrupting the
murine Cp gene. It has been reported that Cp −/− mice are normal at birth, but demonstrate
progressive accumulation of iron in the liver and spleen over the age of the animals. The
mild (compared to the aceruloplasminemic patients iron overload) phenotype in Cp

−/−

mice suggests at least partial compensation of ferroxidase activity by hephaestin

48

.

Hephaestin is a copper-containing transmembrane protein that transports dietary iron
from intestinal enterocytes into the blood. It is widely accepted that Cp and hephaestin
compensate each other in intestinal iron absorption 48 since Cp was also demonstrated to
play important role intestinal iron absorption upon acute iron deficit induced by
phlebotomy 32.

Wilson's Disease
Wilson’s disease is caused by a mutation in the gene coding for P-type ATP-ase,
also known as a Wilson's disease protein. The mutation greatly impairs the delivery of

8

copper to apo-Cp and, instead, the metal ions accumulate in mainly hepatocytes, where
they cycle between Cu1+ and Cu2+ forms leading to production of hydroxyl radicals.
Copper ions also reside in parts of brain and cornea, where (including liver) they
intoxicate the cells. As a result of such pathologic accumulation of copper in above
tissues causes cirrhosis, neurological degeneration, and characteristic Keiser-Fleischer
rings. Kaiser-Fleischer rings observed in the eyes of all Wilson's disease patients are due
to copper deposition in Descemet's membrane of the cornea 55. In addition, low levels of
plasma Cp is characteristic in most of Wilson's disease patients.

Bactericidal activity of Cp
Cp, when combined with Fe2+ at pH 5.0, is bactericidal to Escherichia coli.
Interestingly, the observed effect is biphasic, i.e., killing increased with the ceruloplasmin
to a maximum with Cp concentration of 1 g/ml and then decreased as its concentration
was further increased up to 100 g/ml. It is thought that the bactericidal effect of Cp,
unaffected by catalase or superoxide dismutase, is lost at higher concentrations of Cp due
to more extensive oxidation and quick loss of Fe2+ 56.

Cp and myeloperoxidase (MPO) interaction
MPO, a major protein in neutrophils, catalyzes reaction between H 2 O 2 and halides
to produce a highly cytotoxic product, hypochlorous acid (HClO) 57. Cp was reported to
bind and inhibit MPO's destructive enzymatic activity. Interestingly, during Cp-MPO
interaction, Cp's ability to catalyze oxidation of ferrous ions and to remove peroxides
remains intact 56,58.

9

PART B. INFLAMMATORY BOWEL DISEASE

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the
gastrointestinal (GI) tract that affects millions of people worldwide 59. In addition to most
common clinical symptoms such as abdominal pain, bloody diarrhea, and weight loss 60,
progressive disease is often accompanied by granulomas (focal collection of immune
cells), submucosal edema, lymphoid hyperplasia, ulcerative lesions, and fibrosis

61 62

.

IBD can also be complicated by extraintestinal manifestations such as pleuritis, tendinitis,
and arthritis as illustrated in Figure 1.1. Two major manifestations of this disease are
known as Crohn's disease and ulcerative colitis. Described by and named after Burril B
Crohn

63

, Crohn's disease may affect any part of the GI tract from mouth to anus,

whereas, ulcerative colitis is limited to the large intestine. Ulcerative colitis histologically
differs from Crohn's disease by localized inflammation observed in upper layers of the
colon mucosa

64

. However, both Crohn's disease and ulcerative colitis are characterized

by clinical relapses and disease remissions

65

. The diagnostic difference of Crohn's

disease and ulcerative colitis is described in table 1.1.

Epidemiology
The incidence rates of IBD in developed countries such as USA and UK has been
reported to be the highest but stabilizing, whereas the rates are on the rise in most
developing countries of Europe and Asia

59

. The variation is also observed within the

countries and regions as well where incidence changes from one ethnicity or race to
another. For example, the prevalence of Crohn's disease in North America among white

10

Figure 1.2. Common extraintestinal manifestations of IBD. The figure and legends
adapted from Baumgart and Carding, 2007.

11

Table 1.1. Differential diagnosis of ulcerative colitis and Crohn’s disease. The figure and
legends adapted from Baumgart and Carding, 2007.

12

and African-American individuals is 43 and 29 per 100,000, respectively, while it is only
5 per 100,000 in Asian people 66, which suggests that environment and lifestyle affect the
incidence and prevalence of IBD 67.

Crohn’s Disease
As a relapsing inflammatory disease of the gastrointestinal mucosa Crohn’s disease
is not restricted to a part of the GI tract. The disease discontinuously affects various
portions of the GI tract and develops complications including abscesses, fistulas, or
strictures

68

. According to the Vienna classification, at the time of diagnosis Crohn’s

disease is stricturing in 17%, penetrating (fistulas or abscesses or both) in 13%, and nonstricturing and non-penetrating in 70%, of all patients

69

. It is also generalized that the

disease behavior may fluctuate and change anatomical location. In addition, the clinical
symptoms which include bowel obstruction, fever, abdominal pain, and diarrhea, also
depend on the specific part affected by the disease. Statistical data shows that at the first
diagnosis Crohn’s disease was observed in the terminal ileum in 47%, the colon in 28%,
the ileocolon in 21%, and the upper gastrointestinal tract in 3% of patients 70 69.

Ulcerative Colitis
Ulcerative colitis is a relapsing inflammatory disease that is restricted to the colon.
Unlike Crohn's disease, it is not transmural, i.e., affecting the entire thickness of the wall
of an organ. Anatomic extent of the disease defines the subtype as pancolitis (involving
the entire large intestine), left-sided colitis (involving the sigmoid colon and/or the
descending colon), or proctitis (inflammation of the rectum). Occasionally patients also

13

develop backwash ileitis (ileal inflammation) that make it similar to Crohn's disease and
complicates the differentiation of ulcerative colitis from Crohn’s ileocolitis. Typical
symptoms of ulcerative colitis include abdominal cramping during bowel movements,
passage of pus, mucus, and bloody diarrhea 68.

A follow up study on patients with ulcerative colitis revealed overall normal life
expectancy 71. Interestingly, in the first decade of their life following diagnosis, a quarter
of patients are in remission and about a fifth have a relapsing disease every year. In
addition, clinical remission is seen in half of the patients at a given time. Disease activity
in the prior year very often serves as a significant predictor of relapse. Following the first
10 years, about a quarter of patients have colectomy and more than half the patients
proximally progress during the next 25 years. In this period regression is observed in
75% of case with extensive disease

72 73

. Remarkably, such a distribution of of disease

activity in ulcerative colitis patients is known to be constant from year to year 72.

Endoscopy and histological analysis are the primary tools in diagnosis of ulcerative
colitis

74

. Figure 1.2 shows a picture of the descending colon taken at endoscopy and

hematoxylin & eosin staining of the mucosal biopsy of diseased colon. Three levels of
disease activity are most commonly used to describe the stage of the disease. First level is
called "mild", and it is characterized by up to four stools a day and lack of toxicity 75 76.
Four to six stools daily with minimal toxicity comprise the "moderate" level of disease
activity. And, third level, "severe", is characterized by more than six stools a day and
include symptoms as anemia, fever, and tachycardia (accelerated heart beat) as general

14

A

B

Figure 1.3. Colonoscopy and biopsy images of UC. A) Descending colon: pancolitis with
irregular surface due to extensive ulcerations, spontaneous hemorrhage, and
pseudopolyps. B) Mucosal biopsy: active ulcerative colitis with marked architectural
distortion, cryptitis, and crypt abscesses. Original magnification 100x, H&E. The figure
and legends adapted from Baumgart and Carding, 2007.

15

signs of systemic toxicity. Some patients develop fulminant (rapidly progressive)
ulcerative colitis with more than ten bloody stools daily and continuous bleeding. In such
patients, who also develop high fevers and high levels inflammatory markers, anemia
requires blood transfusion 77.

Oral administration of 5-aminosalicylic acid compounds, a common antiinflammatory drug, is a major therapeutic approach to treat mild to moderately active
ulcerative colitis in outpatients with left-sided disease. In addition to 5-aminosalicylic
acid, enemas or foams are also used to fight more extended disease that can affect larger
portions of left colon. Corticosteroid treatment (prednisolone or azathioprine) is required
in cases with severe, nonfulminant disease or irresponsiveness to 5-aminosalicylic acid
compounds 68.

Because of the risk of systemic toxicity, inpatients with severe, rapidly progressive
(fulminant) colitis are often considered for emergency colectomy. However, when the
severe disease is not accompanied by toxicity and is limited to focal abdominal
tenderness, medical therapy is preferred to colectomy. Such therapy involves intravenous
injections of corticosteroids and fluids to prevent severe dehydration 68.

Immune System
One of the fundamentals of human survival is uncompromised immunity. Our
immune system is extremely sophisticated with its ability to distinguish self from nonself
and capacity for memory. Recent advances in understanding of physiologic immune

16

responses explain the pathogenesis of immunologic disorders and provides new insights
on therapeutic approaches

78

. As a "body" of molecules and cells with specialized

functions in defending against infection, human immune system facing a threat such
infection, deploys two fundamentally different types of responses. Innate immune
responses act to the same extent regardless of the number of times it encounters the same
infectious agent, whereas adaptive immunity wages a more powerful response upon each
repeated exposure to a given antigen 79.

Innate Immunity and Its Cellular Components
Two major characteristics of innate immunity are lack of memory and immediate,
unchanged response to the encountered antigen. Such immune responses are sometimes
referred to as "primitive" as they are present in simple organisms as well. However, the
human innate immune response is complex enough to cause fatalities upon defects in one
or more of its mechanisms. A common example of such disorders is chronic
granulomatous disease with defective killing of phagocytosed microorganisms 79.

The cellular components of the innate immune system include natural killer cells,
mast cells, eosinophils, basophils, macrophages, neutrophils and dendritic cells, all of
which identify and eliminate a wide variety infectious agents 80. However, these cells also
have distinct mechanisms of detection and elimination of a threat. For example,
macrophages derived from circulating monocytes discriminate between "self" and "nonself" molecules by expressing receptors for certain microbe-specific carbohydrates 81.

17

Recruitment and activation of neutrophils and macrophages at the site of infection
in an attempt to destroy pathogens is a key feature of innate immunity 82,83. This feature is
an area of intense research as it may lead to the development of new anti-inflammatory
therapies. Inappropriate response at this level of inflammation is known to be a key
mechanism in several diseases including vasculitis and systemic inflammatory response
syndrome 84. Activated macrophages infiltrating the infected tissue release cytokines that
stimulate proliferation of myeloid precursors in the bone marrow, which ultimately leads
to the release of millions of neutrophils into the blood. These cells are also recruited to a
site of infection via a complex process involving expression of adhesion molecules and
chemokines. In addition to phagocytosis of infectious microorganisms, there are two
known mechanisms of neutrophil-mediated killing. First, by means of a respiratory burst
that involves production of toxic oxygen metabolites (singlet oxygen, hydrogen peroxide,
and hydroxyl radicals). Second, the so-called oxygen-independent response that utilizes
the highly destructive enzymes such as myeloperoxidase and lyzozyme that are stored in
the cytoplasmic granules 85.

Another important function of macrophages and neutrophils is phagocytosis of the
body's dying cells. This function eliminates the threat of necrosis as it triggers
inflammation. Dying cells express phosphatidylserine on their cell surface which
identifies them for phagocytosis 86.

Another group of blood nonphagocytic granulocytes called eosinophils are
responsible for the protection of the host from nematode (round worm) infections.

18

Eosinophils attach to the surface of the parasite already precoated with antigen-specific
IgE and release large granules containing highly cytotoxic group of proteins including
major basic protein, eosinophilic cationic protein, eosinophil peroxidase, and eosinophilderived neurotoxin 83.

Natural killer cells are the major cytotoxic component of innate immunity and
morphologically they resemble lymphocytes. However, natural killer cells do not act in
an antigen-specific manner. They can recognize infected cells by immunoglobulin
receptors (FcR) which bind antibody-coated pathogens. This is known as antibodydependent cellular cytotoxicity. Or, they attempt to bind MHC class I on target cells by
expressing specific MHC I-specific receptor. If the cell is infected and displays a foreign
antigen on its MHC I, the interaction with the natural killer cell is blocked. The activated
natural killer cell then lyses the target by secreting proteins called perforins onto the
surface of the infected cell. Perforins form pores in the cell membrane which ultimately
lead to the transfer of granzymes into the cytosol and induction of apoptosis in the target.
Granzymes are serine proteases that induce apoptosis in cells by cleaving and activating
caspases, one of the major mechanisms of programmed cell death83.

All nucleated cells of the human body express MHC I on their surface. However, as
a consequence of interference of infectious agent with the expression machinery,
sometimes this ability is lost. Therefore, the lack of MHC I on the cell surface leads to
the disappearance of the inhibitory signal during natural killer cell-target cell interaction,
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which results in natural killer cell killing the abnormal target cell by the mechanism
involving perforins and cytotoxic granzymes83.

Basophils and mast cells bear high-affinity receptors for IgE and it is believed that
basophils develop into tissue mast cells 87. Evidence suggest the importance of these cells
in allergies, in which allergen binding to the IgE cross-links the receptor expressed on
their surface. IgE cross-linking triggers the cells to secrete inflammatory mediators
(histamine and prostaglandins) 88. Despite the low frequency of basophils and mast cells,
their involvement in some of the most severe immunological reactions (angioedema and
anaphylaxis) emphasizes the overall importance of their role in innate immune
response83.

Interdigitating dendritic cells, believed to play a key role in innate immunity,
constantly endocytose and sample extracellular fluids in search of a foreign antigen. Once
the pattern-recognition receptors expressed on their surface recognize pathogenassociated molecular patterns of microorganisms, dendritic cells become activated and
function as antigen-presenting cells. The signals that activate these cells can be either
endogenous (interferon- and heat-shock proteins) or pathogen-associated (yeast-cellwall mannans and lipopolysaccharides)

89

. Upon activation dendritic cells increase

expression of CD80 and CD86 surface markers known as costimulatory molecules. These
molecules provide additional (to antigen receptor interaction) signals necessary for
lymphocyte activation when activated dendritic cells migrate to draining lymph node.
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Pattern Recognition Receptors
Some molecules produced by pathogen and/or microbes are not found in higher
organism (vertebrate). Such microbe-specific molecules (very often essential pathogen
components), also known as pathogen-associated molecular patterns (PAMPs), are
recognized by the innate immune cells via pattern-recognition receptors
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. Two major

groups of these receptors are Toll-like receptors (TLRs) and cytosolic nucleotide-binding
oligomerization domain (Nod)-like receptors (NLRs) 91.

TLRs is a family of transmembrane proteins that consist an extracellular domain
containing leucine-rich repeats (LRRs) and an intracellular domain which is a conserved
signaling module called a Toll/IL-1 receptor (TIR) domain. TLRs are mainly expressed
by macrophages, neutrophils, and dendritic cells, and are key to the activation of these
cells by PAMPs 91,92. Twelve mammalian TLRs and a number of their naturally occurring
ligands have been identified to date. The most widely known examples are TLR 3, TLR4,
TLR5, and TLR9 that recognize double-stranded RNA, lipopolysaccharide (LPS),
flagellin, and CpG DNA (nonmethylated bacterial DNA), respectively. Upon ligandreceptor interaction, a conserved signaling cascade is triggered and results in activation of
several transcription factors including IRFs (IFN-regulatory factor transcription factors),
AP-1, and NF-κB
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. These transcription factors initiate or increase the expression of

proinflammatory genes necessary to activate innate and adaptive immunity.

The NLR family is composed of 23 cytosolic proteins characterized by the presence
of a conserved Nod. The general domain structure of cytosolic receptors include an
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amino-terminal effector binding region, pyrin, or baculovirus inhibitor repeat domains,
and carboxyl-terminal LRRs. The effector binding region contains of protein-protein
interaction domains such as caspase recruitment domains (CARD), and the LRRs are
required to detect specific PAMPs 94. In response to the ligands (PAMPs), NRLs activate
intracellular signaling cascade via RICK kinase oligomerization which leads to the
activation of MAPK and NF- B, and induction of proinflammaotry genes.

Soluble Factors in Innate Immunity
In addition to cellular components, innate immune responses frequently involve
acute-phase proteins, complement proteins, and cytokines. Besides their phagocytic
activity, neutrophils and macrophages also express receptors for antibodies and
complement system components, which substantially facilitates phagocytosis of
microorganisms coated with antibodies and/or complement proteins 95. The complement
system consists of about 20 serum glycoproteins and as a whole plays an important role in
innate immunity. The activation of complement system proteins happens in a cascade
sequence at the end of which the initial single molecular stimulus leads to the generation
of thousand-fold more molecules. Three pathways of complement activation activated by
various foreign substances are outlined in figure 1.3. Briefly, these pathways are the
"classical", driven by antigen-antibody reactions, the "alternative" activated by
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Figure 1.4. The three pathways of complement activation. Regulatory proteins are shown
in orange. Components of activation pathways are shown in green. The figure and
legends adapted from Parkin and Cohen, 2001.
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polysaccharides from yeasts and gram negative bacteria, and the "mannan binding lectin"
pathway, stimulated by mannose containing proteins of viruses and yeasts 96.

The acute-phase proteins contribute to the repair of damaged tissue and increase
resistance to infection
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. The well-known example are C-reactive protein, proteinase

inhibitors, coagulation proteins, serum amyloid A protein, and ceruloplasmin. As the
name implies, the serum levels of acute-phase proteins changes in response to infection,
inflammation, and tissue injury79.

Cytokines, another group of soluble mediators highly involved in the regulation of
immune responses, function as signaling molecules messengers necessary for
communication within the immune system and between the immune system and any other
tissue 98. Cells "sense" the cytokines by expressing cytokine specific receptors, which can
be either in soluble or membrane-anchored forms

99,100

. These signaling molecules play

an important role in defense by inducing a variety of responses in a target cell. For
example, the interferons, secreted by virally infected cells, induce viral resistance in the
neighboring cells 101.

Adaptive Immunity
Adaptive immunity is characterized by the use of antigen-specific receptors on T
and B lymphocytes and their activation by innate immune elements. The cellular
components of the innate immunity harvest the antigen and present it to naive T or B cell.
This process, which normally occurs within the lymphoid tissue, is called antigen
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presentation and it leads to the activation and differentiation of the lymphocytes into an
antigen specific effector cell. Depending on the cell type, the effector response can be
either by the activated T lymphocytes directed to the disease site, or by mean of antibody
secretion from activated B lymphocytes (plasma cells) into the blood and tissue fluids 79.

Gut immunity
Intestinal mucosa form a physical zone of interface between the outside world and
immune system (Figure 1.4). Human intestinal tract bears a substantial part of the
mucosa-associated lymphoid tissues and is home to very diverse microbiota that consists
of over 500 species of bacteria alone 102.

Several important intestinal functions are regulated by the gut microflora. These
functions include but limited to angiogenesis, xenobiotic metabolism, nutrient absorption,
and postnatal intestinal maturation

103

. Following birth, initial colonization of the

intestines depends on such factors as delivery (vaginal or caesarean) and feeding (breast
or formula), and begins with domination of aerobic species which later yield anaerobic
commensals. Genetic and environmental (hygiene) factors also influence the colonization
rate and type. The mechanism of establishment of oral tolerance to microbiota remains
largely obscure. However, it is thought that formation of immune tolerance to commensal
microflora as well as maturation of mucosal immune system take place through a
complex interaction of anatomical, cellular, and humoral factors which suppresses
immunologic reaction to antigens entering the GI tract via oral route 104.
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Figure 1.5. Intestinal immunity in healthy state. M-cell = microfold cell. Th = T helper
cells. Th0 = naive T cell. Th, Th1, Th2, Th17 = effector T cells. Tr, Th3=regulatory T
cells. B=B cell. B(PC)=plasma cell. NK=natural killer cell. NKT=natural killer T cells.
The figure and legends adapted from Baumgart and Carding, 2007.
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Epithelial barrier, a polarized single layer covered by mucus that hosts commensal
microflora, is the first line of defense of the mucosal immune system 105. The importance
of mucus in intestinal immunity has been emphasized by studies that report Crohn’s
disease and ulcerative colitis patients with defective mucus production 106,107. In addition
to mucus, the apical surface of single cell gut epithelium is also lined with secretory IgA
and a glycocalyx (a meshwork of acidic mucopolysaccharides and glycoproteins). There
are two routes that substances use to cross this layer, transcellular (through channel and
membrane pumps) and paracellular (controlled by tight junctions). Paneth cells,
specialized epithelial cells of small intestines, are a part of first line of defense in
intestinal immunity as they regulate of microbial density and protect neighboring stem
cells by secreting various antimicrobial peptides such as defensins 108.

Intestinal epithelium is also the site for primary level of antigen recognition

109

.

Pattern recognition receptors are constitutively expressed by epithelial cells and
structurally related receptors that recognize specific microbial components, also called
pathogen- (or microbe-) associated molecular patterns 68.

There are two important families of pattern-recognition receptors that play
important role in gut immunity. The first family, TLRs, recognizes specific targets
associated with a particular microbe or group of microbes. TLR recognize a wide variety
of microorganisms activates both innate and adaptive antimicrobial responses via a
intracellular signaling pathways. Signaling via TLR pathways activates several
transcription factors such factor nuclear factor kappa B (NFκB), which ultimately results
in production of proinflammatory cytokines and chemokines 110. However, under normal
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homeostasis and absence of pathogens, TLR-ligand (microbe-associated molecular
patterns) interactions are also necessary to the and maintenance of an intact epithelial
barrier 111.

The second important family of pattern-recognition receptors are cytosolic NOD
proteins. These proteins, namely, NOD1 and NOD2, are expressed by antigen-presenting
cells and contribute to intestinal mucosa by forming an additional defense mechanism112.
In the absence of proinflammatory signals, epithelial cells also express NOD1 and NOD2
at very low level. However, the expression increases upon activation by proinflammatory
cytokines113. NOD proteins are thought to contributes to the innate immune response to
pathogens because muramyl dipeptide, peptidoglycan constituent of bacterial cell wall
and ligand for NOD2, triggers the activation of NFκB in NOD2 overexpression
models114,115. In general, the function of NOD2 in intestinal epithelia (as the primary
point of interaction with enteric microbes) requires more thorough investigation 116.

Lymphoid tissue of mucosa consists of loose connective tissue beneath the
epithelium (called lamina propria) that hosts mast cells, granulocytes, natural killer (NK)
cells, T cells, and B cells. Antigens and microbes are channeled through the epithelial
layer to the underlying lymphoid clusters. In these clusters, known as Peyer's patches and
lymphoid follicles found in small intestines and colon, respectively, antigens are
harvested by dendritic cells and macrophages117. Dendritic cells, crucial in tolerance
towards commensals and detecting pathogens, can also directly sample bacteria by
sending cytoplasmic extensions (dendrites) through the tight junctions between epithelial
cells118. The distinguishing characteristic of dendritic cells is their expression of all the
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TLRs and NODs, which empowers them to either activate or suppress T cell immunity in
response to pathogens or commensals

110

. These cells create tolerance to an antigen by

stimulating naive T-cell differentiation into regulatory T cells that express transforming
growth factor beta (TGF-) and/or IL-10 (suppression of T cell immunity). They can also
drive T-cell differentiation into effector Th1 (interferon γ+, interleukin 2+) or Th2
(interleukin 4+, interleukin 10+) cells, thereby, activating proinflammatory T cell
immunity (activation of T cell immunity) 119.

Intestinal immune system in disease
Experimental evidence suggests that inappropriate inflammatory response at
various levels of intestinal immunity to the commensal microflora or luminal antigens is
the main trigger of IBD
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. These probably overlapping pathways shown in figure 1.5

and discussed below.

It is wide accepted that the primary inflammatory events in IBD begin with the
"leakiness" of the epithelial barrier. Higher permeability of the epithelium and mucosa in
inflamed and non-inflamed mucosa during Crohn’s disease and ulcerative colitis supports
the idea that clinical onset of the disease in certain patients is led by an already present
defect

120,121

. Several studies have shown the genetic risk factors of epithelial

permeability associated with IBD. These risk factors include, but not limited, to
mutations in CARD15 gene, dysfunction of enteric neurons, and T cell mediated
disruption of tight junctions120,122,123.
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Figure 1.6. Intestinal immune system in IBD. MLN = mesenteric lymph node. Other
abbreviations spelled out in footnote of figure XX1. The figure and legends adapted from
Baumgart and Carding, 2007.
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Besides leakiness of the epithelium, IBD patients also have defective innate
immune system at the mucosal level. For example, in healthy individuals there is a
basolateral expression of TLR3 and TLR5 with slightly detectable level TLR2 and TLR4.
Whereas, TLR 4 expression is higher in Crohn's disease and ulcerative colitis patients.
Interestingly, epithelium affected with Crohn's disease is also characterized with
downregulated TLR3
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. Chronic intestinal inflammation may also display upregulation

of NOD2 in diseased epithelium with activated NFκB signaling pathway 113.

Defective pattern-recognition receptor responses also has a proinflammatory impact
on gut immunity as abnormalities of antigen recognition and processing by professional
antigen-presenting cells (dendritic cells and macrophages) have also been reported in
people with IBD. In such cases, improper recognition of microbiota induces Th1 and
Th17 mediated immunity resembling an attack against pathogens

125

. Intestinal

inflammation increases the number of these antigen presenting cells in inflamed mucosa
and the extent of inflammation in IBD patients correlates with frequency and ratio of
activated (mature) and naive dendritic cells 126. Experimental evidence also suggests that
dendritic cells with defective immunoregulatory function might be responsible for the
repeated activation of memory T cell populations or the absence of peripheral tolerance
(deletion of over-reactive T cells), thereby, aggravating inflammation in IBD
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.

Insufficiency of reagents specific to intestinal dendritic cells and their low frequency are
the major obstacles for the investigation of their role in IBD 116.
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In the presence of inflammatory cytokines non-professional antigen-presenting cells
such as epithelial cells, gain activated phenotype and become potent effector-T-cell
activators in patients with IBD

128

. In addition to classical major histocompatibility

complex molecules, such epithelial cells basolaterally express CD1d known as nonclassical major histocompatibility complex molecule that plays an important role in T cell
activation. In addition, expression of alternative costimulatory molecules by epithelium in
IBD patients might alos contribute to the antigen-presenting function of these cells 129.

Under certain circumstances activated T cells may fail to undergo apoptosis
resulting in failure of either central or peripheral tolerance, presenting yet another level of
abnormal gut immunity. Such a defective clearance of autoreactive T-cell populations has
also been observed in people with Crohn’s disease 130,131. Moreover, in active IBD naive
T cells differentiation is driven towards the effector T cells phenotype, which results in
dominance of these over the regulatory/suppressor T cells
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. Such an imbalance of

regulatory and effector T cells frequencies has a snowball effect because activated T cells
in Crohn’s disease patients were found to be a primary source of such inflammatory
cytokines as IL-12, IL-18, and interferon γ, which activate macrophages. Activated
macrophages, in turn, secrete TNF-α, IL-1, and IL-6 133,134.

Recent studies demonstrate that IL-17+ T cell (Th17) populations regulates
proinflammatory responses in various tissues. The balance between Th17 and antiinflammatory T cells, determined by TGF- β, is also pivotal for the maintenance of gut
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immune homeostasis

135

. Cytokines such as TGF- β that either sustain or delete Th17

activity may play a key role in the development of chronic intestinal inflammation 136.

Recent studies identified that TNF-α release by macrophages can be inhibited by
acetylcholine (a neurotransmitter of both central and peripheral nervous system), which
emphasizes the impact of neuroimmunological interaction on inflammatory cascade.
Thus psychosocial stress can attenuate the inhibitory effect of nervous system on
immunity and augment the proinflammatory pathways 137. Patients with ulcerative colitis
present overactivation of the sympathetic nerve as a result of stress, which, in turn, causes
altered expression of tight junction proteins in gut epithelium, mast-cell degranulation,
and increased levels of interferon γ 138,139.

Secondary inflammatory events commence with migration of inflammatory cells
from the systemic circulation into the intestinal mucosa as result of the release of
chemoattractants by professional and nonprofessional antigen-presenting cells upon
antigen recognition. Activated mucosal macrophages provide simultaneous up-regulation
of ligands on the vascular endothelium for the adhesion molecules on migrating cells by
secreting cytokines (interleukin 1 and TNF-α) 140,141. Ultimately, these events result in the
tissue damage and stricture formation by the multitude of aggressive metabolites (nitric
oxide, oxygen radicals, prostaglandins, leukotrienes, histamine, proteases, and matrix
metalloproteinases) and that accumulate in the mucosa 142-145.

33

Dextran sodium sulfate induced colitis
Dextran Sodium Sulfate (DSS) induced colitis mouse model is one of most widely
used animal models of ulcerative colitis which involves supplementing the drinking water
of mice with DSS. The induced colitis can be either acute or chronic depending on the
duration of DSS administration, continuous or alternating with water, respectively, which
results in epithelial damage and a robust inflammatory response in the. After about five
days of treatment with 3% (weight/volume) DSS in drinking water, mice lose weight and
develop bloody diarrhea. DSS induced damage and inflammation changes overall
morphology of the large intestine as it becomes thicker and shorter. In addition, extensive
colonic bleeding makes animals anemic. Mice are euthanized at various days of the
treatment course and dissected colons are processed for microscopic analysis.
.
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CHAPTER II
MATERIALS AND METHODS
Animals.
Mice with targeted Cp gene deletion (Harris et al., 1999) were backcrossed for 17 to 19
generations into the C57BL/6J background. MPO−/− mice
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in C57BL/6 background

were kindly provided by Dr. Stanley L. Hazen. 10- to 12-week-old females from Cp−/−,
MPO−/−, and wild-type C57BL/6J controls (WT, The Jackson Laboratory) were used in
all experiments. Animals were housed in specific pathogen-free conditions with free
access to food and water. All studies followed a protocol approved by the Animal Review
Committee of the Cleveland Clinic Foundation.

DSS-induced colitis.
To induce experimental colitis, 8 to 12 weeks old mice were continuously treated with
3% (w/v) DSS (M.W. 40,000 kDa; MP Biomedicals Inc.) ad libitum in drinking water.
For histological, gene expression, and cytokine production studies, mice were sacrificed
after DSS treatment for indicated days. In near survival studies mice were given DSS
containing water for up to 30 days.

35

Scoring of histopathology and colonic bleeding.
Proximal and distal ends of the colons were fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned at 5 μm, and stained with H&E for histopathological
confirmation of smooth muscle cell hyperplasia, epithelial damage, inflammatory
infiltrate, and submucosal swelling. Scoring of histopathology and colonic bleeding was
performed by blinded method.

Immunohistochemistry.
Formalin-fixed and paraffin-embedded colon sections were deparaffinized in xylene and
rehydrated in several changes of alcohol. Samples were then boiled for 10 minutes in
antigen retrieval solution (DAKO) and left at room temperature for 30 minutes. Prior to
incubation for 1 hour at room temperature with primary antibody to CD3 (AbD Serotec),
F4/80 (AbD Serotec), anti mouse neutrophil (AbD Serotec), or Cp (Santa Cruz), slides
were blocked with peroxidase inhibitor (DAKO), protein block (DAKO), and
biotin/avidin blocking solutions (Vector Laboratories). After incubation with biotinconjugated secondary antibody (Abcam) and streptavidin-HRP (Vector Laboratories),
positive signals were visualized by DAB kit (BioGenex) and counterstained with Mayer's
hematoxylin (Sigma).

Whole-colon culture ELISA.
100–200 mg of colon tissue from rectum to cecum was washed in cold PBS
supplemented with penicillin and streptomycin. Each sample was cut into small pieces
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and cultured in 12-well flat bottom culture plates (Falcon) in serum-free RPMI medium
containing penicillin and streptomycin. After 24 hours of incubation at 370C, each culture
well was mixed with 1 ml pipette. The culture supernatant was then collected and stored
at -800C until use. These whole-colon culture supernatants from DSS-treated mice at
various time points were examined for KC and MCP-1 chemokines and TNF-a content
with commercially available ELISA kits (R&D Systems), according to the
manufacturer’s protocol. Estimated cytokine and chemokine level was normalized to total
colon tissue weight. Each time point is an average of 3–4 of mice per group.

Hematologic analysis.
Mouse blood was obtained on various time points of DSS administration by cardiac
puncture of euthanized mice into EDTA tubes (Sarstedt), After vigorous mixing 100 ul of
blood was transferred into a new EDTA tube and diluted with 200 ul of 3% BSA in
1xPBS. The final mixture was analyzed by Advia 120 analyzer. Due to failure of Advia
120 to differentiate between mouse monocytes and lymphocytes, the percentage of
monocytes within WBC population was estimated per sample by blood smear and the
exact number calculated from Advia 120 total WBC readout.

DAB-enhanced Prussian Blue.
Formalin-fixed and paraffin-embedded colon and liver sections were deparaffinized in
xylene and rehydrated in several changes of alcohol. Following 10 minute preincubation
with peroxidase block (DAKO), tissue sections washed in DI water and incubated for one
hour in fresh mixture of 10% w/v solution of potassium ferrocyanide (Sigma) in DI water
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and 20% hydrochloric acid (v/v). Prussian blue signals were enhanced with DAB
substrate kit (BioGenex) and counterstained with Myer's hematoxylin (Sigma).

ABX treatment.
6- to 8-week-old mice were continuously treated with ampicillin (1 g/l; Sigma),
vancomycin (500 mg/l; Sigma), neomycin sulfate (1 g/l; Gibco), and metronidazole (1g/l;
Sigma) ad libitum in drinking water for 4 weeks. After 4 weeks of commensal depletion,
mice were then additionally treated with 3% DSS in drinking water for indicated days
and then sacrificed for histological study and hematologic analysis. For the estimate of
commensal depletion about 50 mg of stool collected from antibiotic-treated and untreated
mice was diluted and ground in 1.5 ml PBS, further diluted 10 times with PBS, fixed with
formalin, and used for SYBR green staining as described in Xiao et. al.. Briefly, fixed
bacteria was filtered through 0.2 mm Whatman Anodisc 25 filter (VWR) and attached
bacteria were incubated in SYBR green solution (SYBR Green 1 nucleic acid gel stain,
Invitrogen). The stained filters were dried, transferred onto a slide, and covered with
mounting medium. Stained microflora was visualized and counted under fluorescence
microscope.

Peritoneal macrophage purification and transfer.
Peritoneal macrophages from wild-type and Cp−/− mice were collected by lavage 4 days
after intraperitoneal injection of 1 ml 4% thioglycollate (Sigma). Cells were washed once
in 1xPBS and positively purified by magnetic bead separation using a biotinylated
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antibody to mouse F4/80 and anti-biotin microbeads (Multenyi Biotec). 107 cells were
injected intraperitoneally into each recipient on days 0, 5, and 10 of DSS treatment.

Bone marrow transplantation.
Bone marrow was isolated from 5 to 6 weeks old C57BL/6J and Cp–/– mice (donors) and
transferred through retroorbital sinus injection into 6 weeks old C57BL/6 or Cp–/–
lethally irradiated recipients. 6 weeks after transfer mice were confirmed for the presence
of transferred genotype in blood and given DSS.

Carbonyl protein determination.
Whole colon sample was isolated and homogenized in 50 mM phosphate buffer
containing 5 mM EDTA and protease inhibitors. Following centrifugation at 10,000 g the
supernatant was used for protein carbonyl content by using protein cabonyl assay kit
(Cayman) according to the manufacturer instructions. Briefly, each sample was split into
two tubes. One tube was incubated with DNPH while the other with HCl solution alone
and served as a control (for corrected absorbance). Following a series of washes with
trichloroacetic acid and a mix of ethanol/ethyl acetate, the final pellet was resuspended in
guanidine hydrochloride. The final solution was used to measure the absorbance at 360
nm and the protein carbonyl was calculated by using the formula:
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CHAPTER III
RESULTS

Experimentally induced colitis is lethal in Cp-null mice.
Induction of colitis in mice by dextran sulfate sodium (DSS) is concentration- and
time-dependent

147

. Therefore, we first confirmed that 3% DSS is sublethal in wild-type

(WT) C57BL/6J female mice. Continuous administration of 3% DSS ad libitum in
drinking water induced acute colitis in WT C57BL/6J mice characterized by appearance
of blood in stool after day 3 and significant weight loss by day 7 (Figure 1A). After the
acute peak of the disease between days 7 and 9, the WT animals showed signs of partial
recovery, accompanied with stabilized weight loss and mild, non-diarrheal colonic
bleeding. Despite the continuous administration of DSS and a chronic, sublethal colitis,
more than 95% of these mice survived for at least 30 days (Figure 1B). Mild colonic
bleeding turned into bloody diarrhea on days 7 and 9 (Figure 1C).

During the same course of DSS administration, C57BL/6 mice deficient in Cp
(Cp-/-) acutely lost more weight than WT mice after day 7 (Figure 1A) and became
moribund by day 14 (Figure 1B). Severe bloody diarrhea appeared in most of the Cp-/-
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Figure 2.1. Experimentally induced colitis is lethal in Cp-null mice. Cp-/- and wild type (WT)
C57BL/6J mice were continuously administered 3% DSS ad libitum in drinking water. (A)
Percent weight change of mice normalized to their weight on day 0. (B) Percent survival (n =
20). p < 0.001 using the ANOVA test. (C) Colonic bleeding score. (D) Colon length of Cp-/and WT mice on day 9 (n = 5). p < 0.01 using the Student T test. (E) Representative
photographs of Cp -/- and WT colon on day 9. Error bars represent ± SEM.
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Figure 2.2. Hematologic parameters determined by Advia 120 hematology analyzer of
blood of Cp-/- and WT animals on various days of continuous DSS administration.
Hematocrit, serum hemoglobin (HGB), and red blood cell (RBC) counts are normalized
to day 0 (n = 5 per time point). Error bars represent ± SEM.
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mice on day 7 and colonic bleeding (Figure 1C) increased parallel to the weight loss.
Bloody stool in Cp-/- mice worsened on day 9 and by the time animals became moribund
the entire colon and caecum lacked any stool and were filled with blood (Figure 1C and
1E). In addition, by day 9 of DSS administration the colon of Cp-/- animals was
significantly shorter than the WT controls (Figure 1D and 1E), which serves as one of the
first indications of more severe colitis.

As has been previously reported
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7

, due to impaired iron homeostasis,

unmanipulated Cp-/- mice are slightly anemic when compared to age and sex matched
WT animals and have about 10% lower mean red blood cell volume and hematocrit.
However, blood samples normalized to day 0 showed higher loss of hematocrit, red blood
cells, and hemoglobin in Cp-/- mice compared to WT controls during the course of acute
colitis, which also confirms that these animals have higher colonic bleeding after day 5
(Figure 2C, 2D, and 2G).

Cp-null mice develop excessive inflammation.
Hematoxylin-and-eosin stained cross-sections of distal colon samples collected
from Cp-/- and WT animals on various days (0 through 9) of DSS administration were
analyzed by blinded method for histopathological changes. The typical mouse colon
architecture on day 0 is indistinguishable between WT and Cp-/- animals. On day 5 of
DSS consumption the mucosa from both groups of animals loses its compact epithelial
cell-lined crypts. However, following day 5 the colon of Cp-/- animals showed
increasingly higher epithelial damage, smooth muscle cell hyperplasia, submucosal
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Figure 2.3. Colon histology. The colon of Cp-null mice develops extensive epithelial
damage and higher colonic inflammation as shown in representative photomicrographs
(magnification, X50; hematoxylin and eosin staining) of colons from WT and Cp-/- mice
at days 0, 5, 7, and 9 of continuous DSS administration.
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swelling, and inflammatory infiltrate compared to WT controls as shown in figure 3 and
figure 4. By day 9 most of the Cp-/- colon exhibits a highly eroded epithelial barrier and
hardly retains any crypt, while these structures are relatively intact in WT controls.
Observed tissue pathology clearly coincided with colonic bleeding in both Cp-/- and WT
animals.

We also determined the nature of inflammatory infiltrate on various days in both
groups by immunohistochemical staining for neutrophils, macrophages, and CD3+ T
cells. Both genotypes had few yet equal numbers of the above infiltrates in lamina
propria of middle colon before DSS administration (day 0). The neutrophil and
macrophage influx, as an indication of colonic inflammation, substantially increases by
day 9 in Cp-/- mice compared to WT controls (Figure 5A and 5B). However, anti-CD3
immunostaining revealed that the increase in CD3+ T cell infiltration of colon lamina
propria of Cp-/- mice was not as dramatic as for neutrophils and macrophages. T cell
infiltration increased in both genotypes over the period of DSS administration but the
sites of extensive epithelial damage in Cp-/- middle colon had as many T cells as the mild
sites of inflammation in WT controls (Figure 5C). This implies that the observed severity
of experimental colitis in Cp-/- mice is not T cell-dependent. Elevated blood levels of
these major infiltrates as well as total WBC measured by Advia 120 were also higher in
Cp-null mice following day 5 of DSS administration (Figure 2A, 2B, 2E, and 2F).
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Figure 2.4. Histopathological analysis of colon tissue sections of WT and Cp-/- animals
on various days of DSS treatment reveals higher scoring of smooth muscle cell (SMC)
hyperplasia, submucosal swelling, inflammatory infiltrate, and epithelial damage of
colons from Cp-/- mice after day 5. See Methods section for a description of the scoring
algorithm. Error bars represent ± SEM. (n = 3 per time point per group).
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Figure 2.5. Immunohistochemical analysis of the inflammatory infiltrate in colon shown
in representative photomicrographs of for mouse (A) neutrophils (anti-neutrophil
allotypic marker), (B) macrophages (anti-F4/80), and (C) T cell (anti-CD3) in WT and
Cp-/- colon rolls on day 9 of DSS administration. X50 magnification.
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Figure 2.6. The level of KC, MPC-1 and TNF- in colon of WT and Cp-/- mice
determined by ELISA on culture supernatants of mouse colon incubated in RPMI with
penicillin/streptomycin overnight at 370C. Error bars represent ± SEM (n = 3 per time
point per group).
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Extensive inflammatory infiltration in Cp-/- mice was also confirmed by TNF-and
chemokine ELISA on colon culture supernatants. Higher amounts of TNF-, and
neutrophil (KC) and macrophage (MCP-1) chemokines were detected in Cp-/- colon after
day 5 (Figure 6A, 6B, and 6C), which coincide with immunohistochemistry for
inflammatory infiltrates, WBC counts, hematocrit loss and colonic bleeding.

As a result, it is clear that upon induction of acute colitis Cp-/- mice develop severe
and lethal colonic inflammation accompanied by increased bloody diarrhea, complete
epithelial erosion, and extensive inflammatory infiltrate primarily consisting of
neutrophils and macrophages.

Depletion of commensal bacteria by broad spectrum antibiotics implies microbiotaindependent function of Cp in colonic inflammation.
Intestinal mucosa functions as a physical and immune barrier against pathogens and
commensal microflora. Inappropriate response to gut microflora is thought to be crucial
to the pathogenesis of human IBD
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. Commensal bacteria also play a major role in

initiation of inflammation in the DSS-induced colitis animal model
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. Depletion of

commensal microflora by antibiotic treatment is commonly used to demonstrate that a
given disease phenotype is dependent on the canonical involvement of microbiota.
However, depletion of gut microbiota also reduces regeneration of intestinal epithelia and
leads to mortality of even WT mice upon continuous administration of DSS
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Figure 2.7. Depletion of intestinal microflora did not decrease the extent of epithelial
damage and inflammation in Cp-/- mice caused by DSS administration. (A) Percent
weight change of mice normalized to their weight on day 0. (B) Percent survival (n = 10).
p < 0.05 using the one way ANOVA test. Hematologic analysis of blood of WT and Cp/- mice showing (C) hematocrit (HCT) loss by day 9 (normalized to day 0) and (D) white
blood cell (WBC) count. (n = 5). p < 0.01 using the Student T test. Error bars represent ±
SEM.
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The question then was whether the severity of colitis in Cp-/- mice is microfloradependent. This was of a particular relevance given experiments that showed ferroxidasedependent bactericidal activity of Cp 56. Therefore, we treated Cp-/- and WT mice with a
mix of four different antibiotics ad libitum in drinking water continuously for four weeks.
Following antibiotic treatment, mice were also given 3% DSS. Upon continuous
challenge with DSS, microbiota-depleted WT mice gradually lost weight and became
moribund between days 16 and 18 of DSS treatment. Surprisingly, Cp-null animals lost
weight more rapidly and became moribund about 7 days earlier than WT controls (Figure
7A and 7B). Depletion of gut microflora was confirmed by SYBR green nucleic acid
staining of homogenized stool, and was estimated to be greater than 99.5% in both groups
compared to untreated controls (Figure 8B and 8C).

Hematologic analysis on day 9 of DSS challenge revealed that Cp-/- mice had higher
hematocrit loss and higher WBC counts compared to WT controls indicating higher
colonic bleeding and extensive inflammation, respectively (Figure 7C and 7D).
Histological analysis of colon sections clearly shows that WT mice had very mild level of
inflammation by day 9 of DSS administration while the epithelial damage and
inflammatory infiltrate in colons from Cp-/- animals was similar to the mice of same
genotype with undepleted microflora (Figure 8A). Unexpectedly, these results indicate
that unlike WT controls, Cp-/- mice develop severe colitis even in the absence of intestinal
microflora. Thus the DSS-induced damage and inflammation in Cp-/- mice is microbiotaindependent. This finding also implies that bactericidal activity of Cp does not play a
major role in colitis.
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Figure 2.8. The colon of Cp-null mice develops extensive epithelial damage and higher
colonic inflammation even with depleted intestinal microflora. (A) Hematoxylin and
eosin staining of colon section of WT and Cp-/- mice on day 9 of DSS administration
following antibiotics treatment. (B) The depletion of microflora was determined by
counting SYBR green positive cells per random field. (C) Representative fields of SYBR
green staining, X500 magnification. Error bars represent ± SEM.
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Severe colitis in Cp-/- mice is not due to pathologic iron accumulation.
Neurodegenerative diseases such as aceruloplasminemia, Alzheimer’s disease,
Parkinson’s disease, and Huntington’s disease share a common significant feature:
increased brain iron accumulation

150

. Because Cp plays an important role in iron

homeostasis by facilitating its loading into the apotransferrin, we wanted to test the
possibility of iron accumulation in the colon, normal or inflamed, that could exacerbate
experimental colitis. We stained colon sections for iron accumulation using DABenhanced Prussian blue stain. Liver sections from WT and Cp-/- mice were used as
controls for low and high levels of tissue iron, respectively. DAB-enhanced Prussian blue
staining of normal and inflamed colon sections from Cp-/- and WT animals did not reveal
a detectable level of iron accumulation (Figure 9A). Although this method detects only
ferric iron, it suggested that there are not any abnormal iron deposits in the colon before
and during the inflammation that could potentially increase the severity of colitis.

Cp-null mice have higher protein oxidation during colitis.
Cp has been widely accepted as an antioxidant because of its ferroxidase activity
that oxidizes toxic ferrous iron to the nontoxic ferric form, and it has been reported that
Cp prevents free radical injury in the central nervous system

151

. Likewise, Cp may also

play a critical antioxidant role in the pathogenesis of experimental colitis by neutralizing
highly reactive ferrous iron and limiting the extent of free radical-induced oxidation at
the sites of inflammation. We tested this hypothesis by determining the level of protein
carbonyl in the colon of Cp-/- and control animals upon induction of colitis.
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Figure 2.9. (A) Prussian blue staining of colon sections on day 9 of DSS administration
reveals no detectable accumulation of iron in mice with both genotypes. WT and Cp-/liver was used as controls for normal iron storage levels and overload, respectively. 100X
magnification. (B) Protein carbonyl content is substantially higher in the colon Cp-/- mice
upon induction of experimental colitis (n = 4 per group per time point). Error bars
represent ± SEM.
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Protein carbonyl content (PCC) in supernatants of homogenized colons was estimated by
spectrophotometric detection of hydrazone produced as a result of reaction between 2,4dinitrophenylhydrazine (DNPH) and protein carbonyl. Inflamed colon of Cp-/- mice on
day 9 had three-fold higher PCC per colon than WT controls (Figure 9B), which indicates
that colitis in Cp-null mice is characterized by higher level of protein oxidation. The
above experiments indicate that the severity of experimental colitis in Cp-/- mice might
result from the higher ROS activity unleashed in the absence of antioxidant function of
Cp.

Protective role of Cp in colitis may not be due to the Cp-MPO interaction.
One of the proposed anti-inflammatory roles of Cp is its interaction with a highly
destructive myeloperoxidase (MPO), an enzyme secreted by activated phagocytes
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.

Widely used as a disease activity and neutrophil infiltration marker in DSS-induced
colitis, MPO is known for its cytotoxic enzymatic activity which produces oxidants such
as hypochlorous acid

153

. In vitro studies have demonstrated that Cp binds and inhibits

MPO and it has been speculated that this interaction might be a critical inflammatory
control mechanism whereby Cp eliminates excessive activity of MPO 58,152. However, the
in vivo impact of this interaction has not been demonstrated.

Taking advantage of the availability of MPO-null mice, we hypothesized that if the
severity of disease phenotype observed in Cp-/- animals is due to Cp-MPO interaction,
then the systemic absence of MPO should make mice more resistant to DSS regardless of
the presence of Cp. Therefore, we induced colitis in MPO-/- mice and WT controls
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Figure 2.10. Cp-MPO interaction and blood Cp do play a major role protective role in
experimental colitis. (A) Percent weight change of WT and MPO-/- mice normalized by
weight on day 0, and (B) the percent survival (n = 10) of MPO-/- and WT mice (3.5%
DSS). (C) Percent weight change normalized to day 0 and (D) the percent survival of WT
and Cp-/- animals injected with human Cp and continuous administration of 3% DSS (n
= 12).
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with 3.5% DSS lethal to the WT animals. Surprisingly, observed colitis in MPO-/- mice
was similar in severity to the WT controls, and deficiency in MPO did not have a
significant impact on resistance to DSS in terms of weight loss and survival during acute
DSS-induced colitis (Figure 10A and 10B). Thus, contrary to the speculations that CpMPO interaction may play an important anti-inflammatory role, it is unlikely to account
for the severe DSS-induced colitis phenotype in Cp-/- mice.

Hepatic Cp does not protect against colitis.
Mouse Cp bears 83% amino acid sequence identity to human Cp. Our laboratory
had previously shown that purified human Cp injection into Cp-/- mice substantially
increases serum iron and transferrin saturation and restores the activity of endogenous Cp
in iron homeostasis

7 32

. The same study also demonstrated the stability and activity of

intraperitoneally (I.P.) injected human Cp in Cp-null mice, and estimated the half-life of
injected Cp to be about 30 hours. In addition, the injected human Cp was localized to the
epithelia of small intestine 7. Similarly, we attempted to rescue the C-/- mice from severe
experimental colitis by injecting the animals with purified human Cp. Because the 400 g
of injected Cp stays at detectable activity levels in the blood for at least 48 hours 7, we
repeated Cp injections every other day for the course of acute colitis (two weeks) to
mimic its synthesis in the liver and secretion to the bloodstream. It is very unlikely that
I.P. injections of Cp would immunize the animals to human Cp and create neutralizing
antibodies because the acute phase of the disease during which Cp-/- mice become
moribund finalizes in 14 days. Such a short period of time and lack of proper adjuvants
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should not lead to stimulation of a potent adaptive immune response and neutralization of
over a milligram of injected human Cp.
We hypothesized that restoring circulating Cp with purified human Cp would
reduce the severity of experimental colitis in Cp-/- mice. Cp-/- were given the first 500 g
Cp injection (I.P.) one day before DSS administration and injection was repeated every
other day for up to two weeks during which animals were monitored for weight change
and survival. Unexpectedly, Cp-/- mice repeatedly injected with Cp rapidly lost weight
after day 5 and all became moribund within two weeks of continuous DSS administration
(Figure 10C and 10D). This finding indicates that restoring circulatory Cp in Cp-/- mice
and mimicking its secretion by liver does not have any anti-inflammatory impact and
fails to reduce the severity of colitis in these animals. Since our previous studies
demonstrated localization of injected Cp to the intestinal tract 7, we concluded that liverderived Cp does not have anti-inflammatory function.

Bone marrow-derived macrophages are the source of anti-inflammatory Cp.
Failure to reduce inflammation in Cp-/- mice with Cp injections led us to conclude
that anti-inflammatory effect of Cp is independent from its presence in plasma and may
be derived from an extrahepatic source, e.g., spleen, lung, testes, or monocyte
/macrophage lineage

13 14 154

. The only source of Cp among the above candidates that

would deliver the protein differently than others, e.g., by recruiting the secreting cells
directly to the sites of inflammation, was monocyte/macrophage lineage. Therefore, we
performed bone marrow transplantation on lethally irradiated mice and created four
groups: chimeric animals, WT recipients with Cp-/- bone marrow and Cp-/- recipients with
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WT bone marrow, as well as WT and Cp-/- controls receiving WT and Cp-/- bone marrow,
respectively. All animals were rested for at least 6 weeks to allow the transplanted bone
morrow to replace most of the hematopoietic cells of the host, and then given DSS. At the
end of the 6-week period, all chimeric mice were screened for the presence of the
transferred genotype, e.g., the blood of WT animals clearly had Cp-/- genotype and the
blood of Cp-/- animals had WT genotype (data not shown), which shows that the
transferred bone marrow successfully engrafted and completely replaced the host
nucleated blood cells.

Interestingly, upon continuous treatment of these animals with DSS most of the
chimeric mice developed the disease phenotype depending on the bone marrow genotype
and independent from the presence of Cp in the rest of the body. WT animals with Cp-/bone marrow rapidly lost weight and almost all were moribund by day 14, whereas Cp-/mice with WT bone marrow had similar weight loss and survival parameter similar to
those of WT control with WT bone marrow (Figure 11A and 11B). This result also
supports Cp injection experiment since the WT animals with Cp-/- bone marrow are
expected to have WT levels of Cp in blood secreted by liver. In addition, we performed
complete blood analysis of the recipients on days 0 and 9 of DSS administration and
found that Cp-/- recipients with WT bone marrow displayed lower hematocrit loss
(normalized to day 0), corresponding to lower colonic bleeding, and lower WBC counts
on day 9 compared to the WT recipients with Cp-/- bone marrow (Figure 11C and 11D).
In other words, colonic bleeding and WBC counts of Cp-/- mice with WT bone marrow
were similar to WT controls, whereas, the same parameters of WT mice
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Figure 2.11. Bone marrow transplantation rescues Cp-/- and reverses the disease
phenotype in chimeric mice. (A) Percent weight change of mice normalized to their
weight on day 0. (B) Percent survival (n = 10). p < 0.05 using the ANOVA test.
Hematologic analysis of blood of WT and Cp-/- mice showing (C) hematocrit (HCT) loss
by day 9 (normalized to day 0) and (D) white blood cell (WBC) count (n = 5). p < 0.01
using the Student T test. Error bars represent ± SEM.
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with Cp-/- bone marrow were similar to Cp-/- controls. Thus the source of antiinflammatory Cp is bone marrow.

Because monocyte/macrophage lineage is the only known source of Cp, we
attempted to rescue the Cp-/- mice from developing severe colitis by injecting them with
WT thioglycollate-elicited peritoneal macrophages. Similar to the bone marrow
transplantation experiment, there were four groups of macrophage recipients, Cp-/- mice
injected with Cp-/- macrophages (Cp-/- controls), Cp-/- mice injected with WT
macrophages, WT mice injected with WT macrophages (WT controls), and WT mice
injected with Cp-/- macrophages. Each mouse received 2X107 cells on days 0, 5 and 10 of
DSS treatment. As a result, all Cp-/- controls rapidly lost weight after day 7 and became
moribund by day 14, while all WT controls survived the DSS challenge for 30 days with
about 12% weight loss during the first two weeks (Figure 12A and 12B). In contrast, all
Cp-/- mice that were injected with WT macrophages were rescued regardless of the
presence of Cp-null macrophages, e.g., these animals became as resistant to the DSS as
WT controls (Figure 12A and 12B). However, all of the WT animals injected with Cp-/macrophages survived the 30-day period of DSS administration, in a way similar to WT
controls. Based on the above series of experiments we concluded that the source of antiinflammatory Cp that makes Cp-/- mice less susceptible to DSS is bone marrow-derived
macrophages. In addition, WT mice injected with Cp-null macrophages did not become
susceptible to DSS presumably because these animals had endogenous macrophages with
normal Cp production levels. This also implies that Cp-null macrophages are not
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"hyperactive" and do not exert their function by excessively activating other
inflammatory cells such as T cells.

Because estimated purity of macrophages isolated from the mouse peritoneum 4
days after thioglycollate elicitation is about 80% (Current Protocols in Immunology,
14.1.8), other contaminating cells, mainly, neutrophils, T cells, and dendritic cells, could
potentially play a role in reversing the disease phenotype. Therefore, thioglycollateelicited macrophages from WT and Cp-/- mice were positively purified for F4/80 surface
antigen by using magnetic bead separation technique (Multenyi Biotec). The purity was
estimated by flow cytometry for F4/80 and CD11b surface antigens to be more than 97%
from both WT and Cp-/- animals (Figure 13A). Similar to the previous experiment, each
mouse was injected I.P. with F4/80+ cells on days 0, 5, and 10 of DSS treatment.
However, the average number of cells per injection was 107, half the number of cells
injected in the experiment with "total peritoneal" isolate. Injection of F4/80+/CD11b+ WT
cells into Cp-null animals also rescued them from lethally severe experimental colitis
upon continuous administration of DSS.

In summary, the above series of experiments clearly indicate that regardless of the
presence of circulatory Cp secreted by hepatocytes, animals with Cp-null macrophages
develop severe and acute form of experimental colitis. Thus only macrophages recruited
to the inflammatory sites express Cp that plays an anti-inflammatory role in
experimentally induced colitis.
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Figure 2.12. Injection of WT macrophages rescues Cp-/- mice from lethal colitis. (A)
Percent weight change of mice injected with total peritoneal isolate normalized to their
weight on day 0 and (B) their percent survival (n = 10); p < 0.05 using the ANOVA test.
(C) Percent weight change of mice injected with macrophage positively purified for
F4/80 surface antigen normalized to their weight on day 0 and (D) their percent survival
(n = 10); p < 0.05 using the ANOVA test.
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Resident and recruited colon macrophages express Cp.
Together with the macrophage injection data, our findings in hCp injection and BM
transplantation experiments indicate that in order for the Cp to exert its anti-inflammatory
role, it has to be locally produced by macrophages in the diseased colon. To support this
conclusion we examined at the level of Cp mRNA expression in epithelial layer of colon
before and after the induction of experimental colitis. By performing qRT-PCR using
primers specific to secreted form of Cp message and total RNA obtained from the above
samples we found that the Cp expression in colon epithelia of WT mice treated with DSS
for 9 days increases about 15 fold when compared to the level determined in WT mice on
day 0 (Figure 13B). The message was not detectable in epithelium of Cp-/- mice
regardless of the DSS administration. However, the Cp expression was restored in
epithelial isolates of Cp-/- mice injected with WT macrophages to a level approximately
10 times higher than the WT controls on day 0.

It is noteworthy that the amount of Cp produced by all macrophages in a mouse is
very small compared the Cp secreted into the bloodstream by hepatocytes. Then how can
the macrophage Cp have an anti-inflammatory effect while the liver Cp does not? It is
possible that the abundant blood Cp may not be able to reach the optimum concentration
to provide antioxidant protection at the inflammatory sites in this colitis model. Another
possibility for the anti-inflammatory Cp synthesized by macrophage may lie in its
structural distinction from the liver Cp. There are only two known variants of Cp mRNA
that translate into a protein: secreted form mainly made by hepatocytes and an
alternately-spliced, GPI-linked form of expressed by brain astrocytes20
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21

. Despite that

macrophages are known to produce only the secretory form of Cp, we hypothesized that
Cp made by activated macrophages might also be GPI-linked and, thereby, differ from
the canonical Cp secreted by liver. We designed primers specific for secreted and GPIlinked forms of Cp and, similar to the previous experiment, measured by qRT-PCR
mRNA encoding GPI-Cp in colon epithelia of Cp-/- and WT mice. Interestingly, GPIlinked Cp mRNA was detectable at expression levels similar to the secreted form
(compare figure 13C to 13B). We detected the mRNA for membrane-bound and secreted
Cp at 1:1 ratio in WT colon even before the administration of DSS. However, upon
induction of colitis the GPI-Cp mRNA level did not change, and, with increasing mRNA
encoding secreted Cp, the ratio decreased to 1:10. Total RNA obtained from liver and
brain astrocytes were used as controls for secreted and GPI-linked encoding template,
respectively. Astrocytes isolated from mouse brain expressed GPI-linked and secreted Cp
at 1:10 ratio, whereas the same ratio was measured to be 1:500 in liver (data not shown).

Thus the significant amount of GPI-linked Cp mRNA in resident macrophages of
the colon, and increase in secreted Cp mRNA upon induction of experimental colitis,
demonstrates that Cp is effectively delivered to the sites of inflammation by resident and
recruited macrophages of the colon. As a conclusion, this study reveals that antiinflammatory function of Cp in DSS-induced colitis is macrophage-specific.
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Figure 2.13. WT macrophages rescue Cp-/- mice by restoring Cp expression in the gut
during experimental colitis. (A) Purity of elicited peritoneal macrophages used in
macrophage injection experiments determined by flow cytometry. qRT-PCR for (B)
secreted and (C) GPI-linked Cp mRNA normalized to WT day 0 expression. Error bars
represent ± SEM. (D) The difference between the amino acid sequence of secreted and
GPI-linked Cp at C-terminal and approximate location of RT-qPCR primers. Common
/forward (red), reverse/secreted (green), and reverse/GPI-linked (blue). Adapted from
Patel et. al. 21
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CHAPTER IV
DISCUSSION

In this study we report that Cp plays a protective role in experimentally induced
colitis and demonstrate that macrophages recruited to the sites of inflammation, and not
the liver that produces its circulatory form, are the source of anti-inflammatory Cp. Our
findings also suggest that the absence of antioxidant activity of Cp produced by
macrophages is responsible for the severe disease phenotype observed in Cp-null mice
treated with sublethal dose of DSS.

Increase in circulating levels of Cp during the acute phase of inflammation has been
a hint for its anti-inflammatory function. Several studies have shown that Cp antioxidant
activity may play an important role in neurodegenerative disorders such as Parkinson's
and Alzheimer's diseases8,151,155.

Our data coincide with a case report describing a Wilson's disease patient with very
low level of Cp who developed a severe form of ulcerative colitis (UC) intractable to
prednisolone and salazosulfapyridine treatment156. Other complicated cases of UC in
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Wilson's disease patients have also been reported as an unexpected incidence during a
drug study unrelated to inflammation157. Therefore, based on our findings and previously
published research by other groups we speculate that, though they may not develop
spontaneous and frequent inflammatory diseases, aceruloplasminemia and Wilson's
disease patients with very low level of ceruloplasmin are likely to be prone to severe
types of such diseases due to the lack of or deficiency in an important antioxidant enzyme
expressed by macrophages, the ceruloplasmin.

Protein carbonylation is a widely used marker for oxidative modification of proteins
by reactive oxygen species (ROS) 158. Higher protein carbonylation levels in the colon of
Cp-null mice upon induction of ulcerative colitis reported in this study correlates with
several clinical findings. First, evidence suggests that antioxidants may reduce the onset
and severity of inflammatory bowel disease159. Second, antioxidant activity has
previously been presented as a key anti-inflammatory function of Cp and this role has
equally attributed to the secreted liver form160 and GPI-linked form expressed by
astrocytes in the brain161. Third, Kaneko et al. have reported elevated protein carbonyl
content in the brain of an aceruloplasminemic patient compared to a healthy control162
which implies that protein oxidation in Cp-null astrocytes might be an additional cause of
neuronal damage in these patients besides pathologic iron accumulation.

Interestingly, another research group reported that aceruloplasminemic patients also
have increased lipid peroxidation levels in cortex and putamen of the brain163. Since
elevated level of oxidation in brain of Cp-null patients were found independent of
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inflammation, all of the evidence mentioned above indicate that higher levels of protein
carbonylation in the colon of Cp-null mice with experimental colitis is likely to be the
"cause", not the "result", of extensive epithelial damage and inflammation.

We also suggest that Cp plays a major anti-inflammatory role not at the interface of
organism's immunity and environment, e.g., mucosa, but during the inflammation per se,
once the destructive defense mechanisms have been activated. This is supported by the
fact that Cp-null animals, just as the aceruloplasminemic and Wilson's disease patients
with very low level of Cp, do not spontaneously develop frequent inflammatory
abnormalities, but when the disease is triggered by some other factor, it turns into a
severe type of inflammation. Cp may also be acting as a "fire-proof" component of
macrophage exterior as they crawl through the sites of inflammation loaded with highly
toxic reactive oxygen species, which leads to a speculation that this major plasma
ferroxidase found on the surface of macrophages may be necessary for their survival in
highly destructive inflammatory environment.

Since macrophages play an important either pro- or anti-inflammatory role not only
in innate immune responses but also in the adaptive immunity, patients and animals with
Cp-deficient macrophages may also be under risk of developing severe autoimmune
diseases. However, this speculation has to be confirmed by more vigorous statistical and
epidemiological studies on Wilson's disease and aceruloplasminemic patients as well as
trying experimental autoimmune diseases in Cp-null mice.
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Another correlation between our animals study and the related human disease data
in the literature is in individuals and mice heterozygous for Cp deficiency. Mice
heterozygous for Cp deletion have approximately half the normal plasma levels of Cp.
We found that these animals are more resistant to DSS treatment than their homozygous
littermates and display symptoms close to WT controls. This corresponds to heterozygous
aceruloplasminemia patients with half the normal level of blood Cp who believed to be
asymptomatic or develop substantially milder neurological diseases164.

The role of T cells in experimental models of IBD varies depending on whether the
disease is acute or chronic. Some evidence indicate that T cells regulate immunological
response to luminal antigens in the intestines165 and chronic experimental colitis induced
by alternating DSS administration with water is characterized by both Th1 and Th2
cytokines166. On the other hand, the acute type of the same animal model could be
induced in severe combined immunodeficiency (SCID) mice that lack T and B cells
which implies that acute experimental colitis is T cell-independent167. Since the model
used in our study was based on the acute form of the disease, it is unlikely that the antiinflammatory Cp may perform its function via modulating T cell response.

The immunohistochemical staining for CD3+ T cells did not reveal excessive T cell
infiltration in colon of Cp-/- mice compared to the colon of control animals throughout
the acute phase of DSS-induced colitis (data not shown). Moreover, the macrophage
injection experiment, e.g., injection of Cp-null macrophages into WT mice, also supports
this conclusion because the receivers were still resistant to DSS. If Cp-null macrophages
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were able to hyperactivate T cells, or any other effector cells, the WT mice with excess
numbers of injected Cp-/- F4/80+ cells would develop severe colitis similarly to the Cp-/animals. Finally, there is no evidence that Cp may have any effect on T cell function at
normal homeostatic condition or during inflammation. The fact that inflammatory
signaling-deficient mice such as those with a null mutation in MHC class II, T cell
receptor- chain, interleukin-2, or interleukin-10, spontaneously develop chronic
intestinal inflammation168, also denies Cp's interference with or involvement in
inflammatory signaling because neither Cp-null mice nor aceruloplasminemic patients
have frequent and spontaneous IBD.

Persistent DSS-induced colonic inflammation in Cp-null mice following antibiotic
treatment and depletion of more 99.5% commensal microflora correlates with the
function of alternatively-activated macrophage, that is, tissue repair. Cp-deficient antiinflammatory macrophages are likely to be less capable of cleaning the DSS induced
damage and suppressing the resulted oxidant activity which triggers the onset of colitis
even in the absence of gut microbiota.

Since the discovery of Cp-MPO interaction there has been no in vivo study that
would demonstrate its significance. Although the MPO deficiency in mice may have
consequences far beyond Cp-MPO interaction it is still unlikely that this interaction plays
a major role in the colitis phenotype of Cp-/- animals because of the surprising protective
role of MPO in inflammatory disease such as atherosclerosis and experimental
autoimmune encephalomyelitis146,169.
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Membrane-bound, alternatively spliced from of Cp was discovered in the brain
astrocytes20. Because these glial cells has been the only known major source of GPIlinked Cp, its anti-inflammatory potential was limited to neurological disorders. Because
Cp expressed on the surface of macrophages may localize to virtually any inflammatory
site in the body, our study ascribes a wider role to the minor membrane-bound form of
abundant plasma ferroxidase in inflammatory diseases.

Interestingly, a trace amount of GPI-linked Cp is also found in liver, a major wellknown source of the secretory form21. Since our study indicates that the entire
macrophage/monocytes lineage may be a potential source of membrane-bound Cp,
Kupffer cells, the resident macrophages of the liver, might be the origin of Cp's GPIlinked message detected in liver.

The amino acid sequence of canonical secreted Cp differs from the GPI-linked form
by a very short C-terminal sequence; 5 residues of the secreted form are replaced with 30
amino acids of the GPI signal21. Since this is the only known difference between
membrane-bound and secreted forms of Cp, how can the latter lack the anti-inflammatory
function? Because the rest of the amino acid sequence (more than one thousand) is the
same, it is unlikely for the two forms to have distinct catalytic activities. Therefore, we
hypothesize that the local accumulation of Cp around activated macrophages sustained in
part by the GPI-linked form is crucial for the anti-inflammatory function of macrophages.
Although such a role is attributed to the alternatively-activated macrophages, it is yet to
be determined whether the anti-inflammatory function of Cp is specific to a particular
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subpopulation of these inflammatory cells. We also speculate that the source of protective
Cp in neurodegenerative diseases170 is also monocyte/macrophage lineage and not the
liver. Therefore, we propose that creation of tissue-specific expression of ceruloplasmin
will elucidate the role of this abundant and complex enzyme in multiple mechanisms.
Further investigation is also required to confirm that the two alternatively spliced forms
have the same enzymatic activity and that anti-inflammatory function of Cp expressed by
macrophages is GPI-linked. This could be achieved by creating macrophages capable of
expressing only one form of the protein.

As a conclusion, we propose that both alternatively spliced forms of Cp synthesized
by macrophages play important anti-inflammatory role. The major duties of Cp's secreted
form produced by hepatocytes and abundantly present in the plasma, are facilitating iron
transport, neutralize antioxidants entering bloodstream, and keep blood MPO inactive.
The GPI-linked Cp expressed by activated macrophages recruited to the sites of
inflammation, where the plasma form has very limited access, may be crucial for
neutralization of certain reactive oxidant species in the close vicinity to macrophages and,
thereby, protecting and/or assisting them in the tissue repair.
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